Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43854   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    What is the effect of intravenous iron supplementation on cardiopulmonary haemodynamics, exercise capacity and quality of life in patients with IPAH and iron deficiency?

    Summary
    EudraCT number
    		 2010-024585-22
    Trial protocol
    		 GB   DE  
    Global end of trial date
    22 Dec 2017

    Results information
    Results version number
    		 v1(current)
    This version publication date
    09 Oct 2019
    First version publication date
    09 Oct 2019
    Other versions

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    WILK3
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT01447628
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    Imperial College London
    Sponsor organisation address
    South Kensington Campus, London, United Kingdom,
    Public contact
    Luke Howard, Luke Howard, l.howard@imperial.ac.uk
    Scientific contact
    Luke Howard, Luke Howard, l.howard@imperial.ac.uk
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    12 Jul 2019
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    22 Dec 2017
    Global end of trial reached?
    Yes
    Global end of trial date
    22 Dec 2017
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To assess the clinical value of using intravenous iron (ferric carboxymaltose) infusion in iron deficient patients with idiopathic pulmonary arterial hypertension. The primary endpoint will be endurance time at the end of endurance bicycle cardiopulmonary exercise testing at 80% peak work rate determined from the baseline incremental exercise test, measured at 12 weeks after study treatment.
    Protection of trial subjects
    All adverse events were monitored and recorded throughout the trial. No other specific protection.
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    29 Mar 2011
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United Kingdom: 34
    Country: Number of subjects enrolled
    Germany: 5
    Worldwide total number of subjects
    39
    EEA total number of subjects
    39
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    34
    From 65 to 84 years
    5
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 Patients participating in this study are adult males and females with symptomatic IPAH as defined by the eligibility criteria specified in the protocol.

    Pre-assignment
    Screening details
    		 Potential participants will be screened using data collected during their routine outpatient appointment at the Pulmonary Hypertension Service or PH Clinic. Any unavailable or missing data will be collected at the screening visit (week 0) once the patient has provided written informed consent.

    Pre-assignment period milestones
    Number of subjects started
    		 39
    Number of subjects completed
    		 39

    Period 1
    Period 1 title
    Baseline
    Is this the baseline period?
    		 Yes
    Allocation method
    Not applicable
    Blinding used
    		 Not blinded

    Arms
    Arm title
    		 All patients
    Arm description
    		 There are no products specified, as this is the baseline period, prior to randomisation.
    Arm type
    		 Baseline: no intervention

    Investigational medicinal product name
    Ferinject
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    1000mg Ferinject, intravenous infusion

    Number of subjects in period 1
    		All patients
    Started
    39
    Completed
    39
    Period 2
    Period 2 title
    Treatment
    Is this the baseline period?
    		 No
    Allocation method
    Randomised - controlled
    Blinding used
    		 Double blind
    Roles blinded
    		 Subject, Investigator, Data analyst, Carer, Assessor

    Arms
    Are arms mutually exclusive
    No

    Arm title
    		 Active treatment: Ferinject
    Arm description
    		 1000mg Ferinject infused over 15 minutes
    Arm type
    		 Experimental

    Investigational medicinal product name
    Ferinject
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    1000mg Ferinject, intravenous infusion

    Arm title
    		 Placebo: Saline
    Arm description
    		 Saline infused over 15 minutes
    Arm type
    		 Placebo

    Investigational medicinal product name
    Saline
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    1000ml saline for intravenous infusion

    Number of subjects in period 2
    		Active treatment: Ferinject Placebo: Saline
    Started
    39
    39
    Completed
    39
    39

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Baseline
    Reporting group description
    		 -

    Reporting group values
    		 Baseline Total
    Number of subjects
    		 39 39
    Age categorical
    All participants
    Units: Subjects
        In utero
    		 0 0
        Preterm newborn infants (gestational age < 37 wks)
    		 0 0
        Newborns (0-27 days)
    		 0 0
        Infants and toddlers (28 days-23 months)
    		 0 0
        Children (2-11 years)
    		 0 0
        Adolescents (12-17 years)
    		 0 0
        Adults (18-64 years)
    		 34 34
        From 65-84 years
    		 5 5
        85 years and over
    		 0 0
    Gender categorical
    Units: Subjects
        Female
    		 29 29
        Male
    		 10 10
    Subject analysis sets

    Subject analysis set title
    Total population
    Subject analysis set type
    		 Intention-to-treat
    Subject analysis set description
    All participants

    Subject analysis sets values
    		 Total population
    Number of subjects
    39
    Age categorical
    All participants
    Units: Subjects
        In utero
    0
        Preterm newborn infants (gestational age < 37 wks)
    0
        Newborns (0-27 days)
    0
        Infants and toddlers (28 days-23 months)
    0
        Children (2-11 years)
    0
        Adolescents (12-17 years)
    0
        Adults (18-64 years)
    34
        From 65-84 years
    5
        85 years and over
    0
    Age continuous
    Units:
        
    ( )
    Gender categorical
    Units: Subjects
        Female
    29
        Male
    10

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    All patients
    Reporting group description
    		 There are no products specified, as this is the baseline period, prior to randomisation.
    Reporting group title
    Active treatment: Ferinject
    Reporting group description
    		 1000mg Ferinject infused over 15 minutes

    Reporting group title
    Placebo: Saline
    Reporting group description
    		 Saline infused over 15 minutes

    Subject analysis set title
    Total population
    Subject analysis set type
    		 Intention-to-treat
    Subject analysis set description
    All participants

    Primary: Endurance time from start to finish of Cardio-pulmonary exercise test

    		 Close Top of page
    End point title
    		 Endurance time from start to finish of Cardio-pulmonary exercise test
    End point description
    End point type
    Primary
    End point timeframe
    12 weeks post treatment
    End point values
    		 Active treatment: Ferinject Placebo: Saline
    Number of subjects analysed
    39
    39
    Units: seconds
        arithmetic mean (confidence interval 95%)
    315.44 (274.68 to 356.20)
    302.89 (260.09 to 345.69)
    Statistical analysis title
    		 Linear mixed model
    Statistical analysis description
    All primary and secondary efficacy endpoints were analysed using linear mixed models appropriate for a crossover design. The linear models included administration sequence, period and treatment as fixed effects and subject as a random effect, and all models included relevant and statistically significant baseline covariates.
    Comparison groups
    Active treatment: Ferinject v Placebo: Saline
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.7109
    Method
    		 Mixed models analysis
    Confidence interval

    Secondary: Peak VO2 Level at 12 Weeks After Study Treatment

    		 Close Top of page
    End point title
    		 Peak VO2 Level at 12 Weeks After Study Treatment
    End point description
    End point type
    Secondary
    End point timeframe
    12 weeks post study treatment
    End point values
    		 Active treatment: Ferinject Placebo: Saline
    Number of subjects analysed
    39
    39
    Units: litres per minute
        arithmetic mean (confidence interval 95%)
    1.17 (1.10 to 1.22)
    1.13 (1.08 to 1.21)
    Statistical analysis title
    		 Linear mixed model
    Comparison groups
    Active treatment: Ferinject v Placebo: Saline
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.6583
    Method
    		 Mixed models analysis
    Confidence interval

    Secondary: VO2 at Metabolic Threshold

    		 Close Top of page
    End point title
    		 VO2 at Metabolic Threshold
    End point description
    End point type
    Secondary
    End point timeframe
    12 weeks post study treatment
    End point values
    		 Active treatment: Ferinject Placebo: Saline
    Number of subjects analysed
    39
    39
    Units: litres per minute
        arithmetic mean (confidence interval 95%)
    0.78 (0.73 to 0.82)
    0.77 (0.73 to 0.82)
    Statistical analysis title
    		 Linear mixed model
    Comparison groups
    Active treatment: Ferinject v Placebo: Saline
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.9773
    Method
    		 Mixed models analysis
    Confidence interval

    Secondary: VE/VCO2 Slope

    		 Close Top of page
    End point title
    		 VE/VCO2 Slope
    End point description
    End point type
    Secondary
    End point timeframe
    12 weeks
    End point values
    		 Active treatment: Ferinject Placebo: Saline
    Number of subjects analysed
    39
    39
    Units: interger
        arithmetic mean (confidence interval 95%)
    41.15 (39.43 to 42.43)
    42.35 (40.58 to 44.07)
    Statistical analysis title
    		 Linear mixed model
    Comparison groups
    Active treatment: Ferinject v Placebo: Saline
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.1815
    Method
    		 Mixed models analysis
    Confidence interval

    Secondary: VO2 / WR Slope

    		 Close Top of page
    End point title
    		 VO2 / WR Slope
    End point description
    End point type
    Secondary
    End point timeframe
    12 weeks
    End point values
    		 Active treatment: Ferinject Placebo: Saline
    Number of subjects analysed
    39
    39
    Units: integer
        arithmetic mean (confidence interval 95%)
    8.12 (7.50 to 8.71)
    8.04 (7.46 to 8.68)
    Statistical analysis title
    		 Linear mixed model
    Comparison groups
    Active treatment: Ferinject v Placebo: Saline
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.8751
    Method
    		 Mixed models analysis
    Confidence interval

    Secondary: Peak O2 Pulse Rate

    		 Close Top of page
    End point title
    		 Peak O2 Pulse Rate
    End point description
    End point type
    Secondary
    End point timeframe
    12 weeks
    End point values
    		 Active treatment: Ferinject Placebo: Saline
    Number of subjects analysed
    39
    39
    Units: interger
        arithmetic mean (confidence interval 95%)
    8.83 (8.36 to 9.28)
    8.62 (8.17 to 9.08)
    Statistical analysis title
    		 Linear mixed model
    Comparison groups
    Active treatment: Ferinject v Placebo: Saline
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.4813
    Method
    		 Mixed models analysis
    Confidence interval

    Secondary: VO2 at the End of Endurance Cardio-pulmonary Exercise Test

    		 Close Top of page
    End point title
    		 VO2 at the End of Endurance Cardio-pulmonary Exercise Test
    End point description
    End point type
    Secondary
    End point timeframe
    12 weeks
    End point values
    		 Active treatment: Ferinject Placebo: Saline
    Number of subjects analysed
    39
    39
    Units: litres per minute
        least squares mean (confidence interval 95%)
    4.25 (3.5 to 5.01)
    4.49 (3.71 to 5.28)
    Statistical analysis title
    		 Linear mixed model
    Comparison groups
    Active treatment: Ferinject v Placebo: Saline
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.2395
    Method
    		 Mixed models analysis
    Confidence interval

    Secondary: VO2 at 3 mins

    		 Close Top of page
    End point title
    		 VO2 at 3 mins
    End point description
    End point type
    Secondary
    End point timeframe
    12 weeks
    End point values
    		 Active treatment: Ferinject Placebo: Saline
    Number of subjects analysed
    39
    39
    Units: integer
        least squares mean (confidence interval 95%)
    1.29 (0.98 to 1.60)
    1.14 (0.81 to 1.48)
    Statistical analysis title
    		 Linear mixed model
    Comparison groups
    Active treatment: Ferinject v Placebo: Saline
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.4758
    Method
    		 Mixed models analysis
    Confidence interval

    Secondary: Iron Indices: Serum Iron

    		 Close Top of page
    End point title
    		 Iron Indices: Serum Iron
    End point description
    End point type
    Secondary
    End point timeframe
    12 weeks
    End point values
    		 Active treatment: Ferinject Placebo: Saline
    Number of subjects analysed
    39
    39
    Units: umol/l
        arithmetic mean (confidence interval 95%)
    17.15 (15.42 to 18.64)
    15.48 (13.94 to 17.17)
    Statistical analysis title
    		 Linear mixed model
    Comparison groups
    Active treatment: Ferinject v Placebo: Saline
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.2002
    Method
    		 Mixed models analysis
    Confidence interval

    Secondary: Iron Indices: Transferrin Saturations

    		 Close Top of page
    End point title
    		 Iron Indices: Transferrin Saturations
    End point description
    End point type
    Secondary
    End point timeframe
    12 weeks
    End point values
    		 Active treatment: Ferinject Placebo: Saline
    Number of subjects analysed
    39
    39
    Units: percentage
        arithmetic mean (confidence interval 95%)
    26.2 (22.96 to 28.89)
    22 (19.21 to 25.12)
    Statistical analysis title
    		 Linear mixed model
    Comparison groups
    Active treatment: Ferinject v Placebo: Saline
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.0727
    Method
    		 Mixed models analysis
    Confidence interval

    Secondary: Iron Indices: Ferritin

    		 Close Top of page
    End point title
    		 Iron Indices: Ferritin
    End point description
    End point type
    Secondary
    End point timeframe
    12 weeks
    End point values
    		 Active treatment: Ferinject Placebo: Saline
    Number of subjects analysed
    39
    39
    Units: ug/L
        arithmetic mean (confidence interval 95%)
    150.32 (118.63 to 175.51)
    92.74 (66.08 to 122.88)
    Statistical analysis title
    		 Linear mixed model
    Comparison groups
    Active treatment: Ferinject v Placebo: Saline
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.0003
    Method
    		 Mixed models analysis
    Confidence interval

    Secondary: Iron Indices: sTfR

    		 Close Top of page
    End point title
    		 Iron Indices: sTfR
    End point description
    End point type
    Secondary
    End point timeframe
    12 weeks
    End point values
    		 Active treatment: Ferinject Placebo: Saline
    Number of subjects analysed
    39
    39
    Units: nmol/L
        arithmetic mean (confidence interval 95%)
    28.37 (25.73 to 31.72)
    37.25 (34.02 to 40.0)
    Statistical analysis title
    		 Linear mixed method
    Comparison groups
    Active treatment: Ferinject v Placebo: Saline
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.0001
    Method
    		 Mixed models analysis
    Confidence interval

    Secondary: 6 minute walk test: Distance Walked

    		 Close Top of page
    End point title
    		 6 minute walk test: Distance Walked
    End point description
    End point type
    Secondary
    End point timeframe
    12 weeks
    End point values
    		 Active treatment: Ferinject Placebo: Saline
    Number of subjects analysed
    39
    39
    Units: metres
        arithmetic mean (confidence interval 95%)
    426.03 (411.57 to 440.20)
    424.3 (410.06 to 438.70)
    Statistical analysis title
    		 Linear mixed method
    Comparison groups
    Active treatment: Ferinject v Placebo: Saline
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.8093
    Method
    		 Mixed models analysis
    Confidence interval

    Secondary: 6 minute walk test: Borg dyspnoea score after test

    		 Close Top of page
    End point title
    		 6 minute walk test: Borg dyspnoea score after test
    End point description
    End point type
    Secondary
    End point timeframe
    12 weeks
    End point values
    		 Active treatment: Ferinject Placebo: Saline
    Number of subjects analysed
    39
    39
    Units: Units on a scale
        arithmetic mean (confidence interval 95%)
    3.24 (2.75 to 3.75)
    3.68 (3.18 to 4.17)
    Statistical analysis title
    		 Linear mixed method
    Comparison groups
    Placebo: Saline v Active treatment: Ferinject
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.0862
    Method
    		 Mixed models analysis
    Confidence interval

    Secondary: Iron Indices: NT-pro-BNP

    		 Close Top of page
    End point title
    		 Iron Indices: NT-pro-BNP
    End point description
    End point type
    Secondary
    End point timeframe
    12 weeks
    End point values
    		 Active treatment: Ferinject Placebo: Saline
    Number of subjects analysed
    39
    39
    Units: fmol/ml
        arithmetic mean (confidence interval 95%)
    307.64 (186.47 to 437.62)
    424.37 (297.52 to 548.39)
    Statistical analysis title
    		 Linear mixed method
    Comparison groups
    Active treatment: Ferinject v Placebo: Saline
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.1041
    Method
    		 Mixed models analysis
    Confidence interval

    Secondary: Quality of Life: CAMPHOR Activity Score

    		 Close Top of page
    End point title
    		 Quality of Life: CAMPHOR Activity Score
    End point description
    End point type
    Secondary
    End point timeframe
    12 weeks
    End point values
    		 Active treatment: Ferinject Placebo: Saline
    Number of subjects analysed
    39
    39
    Units: Units on a scale
        arithmetic mean (confidence interval 95%)
    9.12 (8.14 to 10.07)
    9.18 (8.25 to 10.16)
    Statistical analysis title
    		 Linear mixed method
    Comparison groups
    Active treatment: Ferinject v Placebo: Saline
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.8948
    Method
    		 Mixed models analysis
    Confidence interval

    Secondary: Quality of Life: CAMPHOR Symptom Score

    		 Close Top of page
    End point title
    		 Quality of Life: CAMPHOR Symptom Score
    End point description
    End point type
    Secondary
    End point timeframe
    12 weeks
    End point values
    		 Active treatment: Ferinject Placebo: Saline
    Number of subjects analysed
    39
    39
    Units: Items on a scale
        arithmetic mean (confidence interval 95%)
    7.94 (6.99 to 8.89)
    7.94 (7.02 to 8.89)
    Statistical analysis title
    		 Linear mixed method
    Comparison groups
    Active treatment: Ferinject v Placebo: Saline
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.9559
    Method
    		 Mixed models analysis
    Confidence interval

    Secondary: Quality of Life: CAMPHOR QoL Score

    		 Close Top of page
    End point title
    		 Quality of Life: CAMPHOR QoL Score
    End point description
    End point type
    Secondary
    End point timeframe
    12 weeks
    End point values
    		 Active treatment: Ferinject Placebo: Saline
    Number of subjects analysed
    39
    39
    Units: Items on a scale
        arithmetic mean (confidence interval 95%)
    7.58 (6.38 to 8.69)
    7 (5.91 to 8.16)
    Statistical analysis title
    		 Linear mixed method
    Comparison groups
    Active treatment: Ferinject v Placebo: Saline
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.2423
    Method
    		 Mixed models analysis
    Confidence interval

    Secondary: Mean Right Atrial Pressure

    		 Close Top of page
    End point title
    		 Mean Right Atrial Pressure
    End point description
    End point type
    Secondary
    End point timeframe
    12 weeks
    End point values
    		 Active treatment: Ferinject Placebo: Saline
    Number of subjects analysed
    39
    39
    Units: TBC
        arithmetic mean (confidence interval 95%)
    6.56 (5.40 to 9.23)
    10.12 (7.17 to 11.21)
    Statistical analysis title
    		 Linear mixed method
    Comparison groups
    Active treatment: Ferinject v Placebo: Saline
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.1221
    Method
    		 Mixed models analysis
    Confidence interval

    Secondary: Peak VO2 Level in ml/min/kg

    		 Close Top of page
    End point title
    		 Peak VO2 Level in ml/min/kg
    End point description
    End point type
    Secondary
    End point timeframe
    12 weeks
    End point values
    		 Active treatment: Ferinject Placebo: Saline
    Number of subjects analysed
    39
    39
    Units: ml/min/kg
        arithmetic mean (confidence interval 95%)
    15.10 (14.10 to 15.58)
    14.67 (14.20 to 15.68)
    Statistical analysis title
    		 Linear mixed model
    Comparison groups
    Active treatment: Ferinject v Placebo: Saline
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.7625
    Method
    		 Mixed models analysis
    Confidence interval

    Secondary: VO2 at Metabolic Threshold measured during incremental CPET

    		 Close Top of page
    End point title
    		 VO2 at Metabolic Threshold measured during incremental CPET
    End point description
    End point type
    Secondary
    End point timeframe
    12 weeks post study treatment
    End point values
    		 Active treatment: Ferinject Placebo: Saline
    Number of subjects analysed
    39
    39
    Units: ml/min/kg
        arithmetic mean (confidence interval 95%)
    10.01 (9.45 to 10.46)
    9.99 (9.52 to 10.53)
    Statistical analysis title
    		 Linear mixed model
    Comparison groups
    Active treatment: Ferinject v Placebo: Saline
    Number of subjects included in analysis
    78
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.7711
    Method
    		 Mixed models analysis
    Confidence interval

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From consent to 24 weeks
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    10
    Reporting groups
    Reporting group title
    All participants
    Reporting group description
    		 -

    Serious adverse events
    		 All participants
    Total subjects affected by serious adverse events
         subjects affected / exposed
    8 / 39 (20.51%)
         number of deaths (all causes)
    0
         number of deaths resulting from adverse events
    0
    Investigations
    Hypophosphataemia
         subjects affected / exposed
    2 / 39 (5.13%)
         occurrences causally related to treatment / all
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    Injury, poisoning and procedural complications
    Fall
         subjects affected / exposed
    1 / 39 (2.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Nervous system disorders
    Spinal haematoma
         subjects affected / exposed
    1 / 39 (2.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    1 / 39 (2.56%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Disease progression
         subjects affected / exposed
    1 / 39 (2.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Reproductive system and breast disorders
    Haemorrhagic ovarian cyst
         subjects affected / exposed
    1 / 39 (2.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Infections and infestations
    Tonsilitis
         subjects affected / exposed
    1 / 39 (2.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    		 All participants
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    35 / 39 (89.74%)
    Investigations
    Hypophosphataemia
         subjects affected / exposed
    4 / 39 (10.26%)
         occurrences all number
    6
    Cardiac disorders
    Palpitations
         subjects affected / exposed
    4 / 39 (10.26%)
         occurrences all number
    4
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    7 / 39 (17.95%)
         occurrences all number
    10
    Headache
         subjects affected / exposed
    6 / 39 (15.38%)
         occurrences all number
    8
    Cough
         subjects affected / exposed
    3 / 39 (7.69%)
         occurrences all number
    3
    Abdominal pain
         subjects affected / exposed
    2 / 39 (5.13%)
         occurrences all number
    2
    Pyrexia
         subjects affected / exposed
    2 / 39 (5.13%)
         occurrences all number
    2
    Ear and labyrinth disorders
    Vertigo
         subjects affected / exposed
    2 / 39 (5.13%)
         occurrences all number
    2
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    4 / 39 (10.26%)
         occurrences all number
    4
    Nausea
         subjects affected / exposed
    3 / 39 (7.69%)
         occurrences all number
    3
    Vomiting
         subjects affected / exposed
    2 / 39 (5.13%)
         occurrences all number
    2
    Respiratory, thoracic and mediastinal disorders
    Epistaxis
         subjects affected / exposed
    2 / 39 (5.13%)
         occurrences all number
    3
    Skin and subcutaneous tissue disorders
    Rash
         subjects affected / exposed
    4 / 39 (10.26%)
         occurrences all number
    4
    Infections and infestations
    Cold
         subjects affected / exposed
    8 / 39 (20.51%)
         occurrences all number
    11
    Respiratory Infection
         subjects affected / exposed
    3 / 39 (7.69%)
         occurrences all number
    3
    Flu symptoms
         subjects affected / exposed
    3 / 39 (7.69%)
         occurrences all number
    3
    Urinary tract infection
         subjects affected / exposed
    2 / 39 (5.13%)
         occurrences all number
    3

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    05 Aug 2011
    Change to eligibility criteria, separate patient documents for participating sites.
    02 Jul 2012
    Change inclusion criterion 3, change of PI at one participating site.
    04 Dec 2012
    Addition of fasting glucose and insulin measurements.
    24 Sep 2013
    Change of PI at participating site
    20 Mar 2014
    Changes to eligibility, reduction in number of protocol clinic visits, removal of week 36 visit and addition of activity monitor.
    25 Jun 2015
    Changes to cardiac cath, activity monitor and replacement of visits 2 and 4 with telephone calls.
    14 Dec 2015
    Addition of German site.

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    Pt 2003, 3004, 4002-05 had endurance CPETs performed at incorrect workloads, so those data were replaced by imputed values. Visit 5 CPETs for 1008, 1018 and 1019 were outside protocol window. 1014 received placebo at both treatment visits in error
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Apr 23 11:13:24 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA